Septerna, Inc. Common Stock (SEPN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) has a cash flow conversion efficiency ratio of -0.068x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.63 Million) by net assets ($378.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SEPN equity to assets ratio to measure how much of total assets are equity-financed.
Septerna, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Septerna, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SEPN operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Septerna, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Septerna, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yangling Metron New Material Co Ltd
SHE:300861
|
-0.003x |
|
Molymet
SN:MOLYMET
|
0.325x |
|
China Railway Construction Corporation Limited
F:4FF
|
0.045x |
|
Galapagos N.V.
AS:GLPG
|
-0.024x |
|
Triangle Tyre Co Ltd
SHG:601163
|
0.012x |
|
Zhejiang Zhongjian Technology Co Ltd
SHE:002779
|
-0.035x |
|
Kernel Holding SA
WAR:KER
|
-0.080x |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
0.006x |
Annual Cash Flow Conversion Efficiency for Septerna, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Septerna, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Septerna, Inc. Common Stock market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $381.93 Million | $110.19 Million | 0.289x | +279.62% |
| 2024-12-31 | $420.05 Million | $-67.47 Million | -0.161x | -115.92% |
| 2023-12-31 | $-38.37 Million | $-38.72 Million | 1.009x | +91.40% |
| 2022-12-31 | $-44.20 Million | $-23.30 Million | 0.527x | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more